Disitamab vedotin plus bevacizumab for HER2-low metastatic breast cancer after T‑DxD failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, single‑arm phase II trial enrolling adults with HER2‑low (IHC 1+ or 2+/ISH‑) advanced or metastatic breast cancer who progressed after prior trastuzumab deruxtecan (T‑DxD). Participants receive disitamab vedotin (RC48) plus bevacizumab per protocol, with tumor response reviewed by an independent committee. The primary endpoint is objective response rate (ORR); secondary endpoints include progression‑free survival, overall survival, disease control rate, and duration of response. Safety is monitored continuously and graded using CTCAE v5.0 with dose modifications and supportive care as needed.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed written informed consent prior to any study-related procedures.
2. Female or male participants aged 18 years or older.
3. Histologically or cytologically confirmed advanced or recurrent/metastatic HER2-low breast cancer (IHC 1+ or IHC 2+/ISH-).
4. Received at least two cycles of trastuzumab deruxtecan (T-DXd) during treatment for recurrent or metastatic disease.
5. At least one measurable lesion according to RECIST version 1.1. A lesion within a previous radiation field may be considered measurable if disease progression is confirmed at that site.
6. ECOG performance status 0-2.
7. Expected survival time \>3 months.
8. Left ventricular ejection fraction (LVEF) ≥50% by ECHO or MUGA within 4 weeks prior to the first dose.
9. Adequate organ function as determined by laboratory assessments per investigator's judgment.

Exclusion Criteria:

1. Uncontrolled comorbid conditions.
2. Clinically uncontrolled pleural effusion, ascites, or pericardial effusion requiring drainage within 2 weeks prior to enrollment.
3. History or current evidence of interstitial lung disease (ILD) or non-infectious pneumonitis.
4. Use of systemic immunosuppressive medications within 14 days prior to the first dose.
5. Clinically significant pulmonary comorbidities.
6. Allogeneic organ transplantation or hematopoietic stem cell transplantation (except corneal transplant).
7. Known hypersensitivity to bevacizumab, disitamab vedotin, or any of their components or excipients.
8. Spinal cord compression or clinically active central nervous system (CNS) metastases.
9. Unresolved toxicities or complications from prior therapy that have not recovered to baseline or ≤Grade 1 (per CTCAE v5.0).
10. Known human immunodeficiency virus (HIV) infection (HIV-1/2 antibody positive).
11. Untreated active hepatitis B infection.
12. Active hepatitis C virus (HCV) infection.
13. Receipt of a live vaccine within 30 days before Cycle 1 Day 1.
14. Pregnant or breastfeeding women.
15. Any severe or uncontrolled systemic disease judged by the investigator to interfere with study participation or safety evaluation.
16. Gastrointestinal perforation or fistula, wound dehiscence requiring medical intervention, wound-healing complications, severe hemorrhage, arterial thrombotic events, or life-threatening (Grade 4) venous thromboembolism, including pulmonary embolism.

Where it's running

• The First Affiliated Hospital with Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Wei Li, Ph.D
• Email: liwei1218@njmu.edu.cn
• Phone: 025-68307102

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Disitamab vedotin plus carboplatin and bevacizumab as first-line and maintenance treatment for HER2-expressing, HRD-negative high-risk ovarian cancer

  This study tests whether adding disitamab vedotin to carboplatin and bevacizumab helps people with HER2-expressing, HRD-negative high-risk ovarian cancer as first-line and maintenance treatment.

  Recruiting Phase 2 Jiangsu Cancer Institute & Hospital · Nanjing, Jiangsu and 1 other locations · NCT07311577

• RC48 with bevacizumab or pyrotinib for HER2-positive metastatic breast cancer after T-Dxd failure

  This trial will try RC48 together with either bevacizumab or pyrotinib in adults with HER2-positive metastatic breast cancer whose disease has progressed after trastuzumab deruxtecan (T-Dxd).

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07065435

• Disitamab vedotin (RC48) with AK104 and bevacizumab for recurrent or persistent clear cell ovarian cancer

  This trial tests whether combining a HER2-targeted antibody–drug conjugate (disitamab vedotin) with the PD-1/CTLA-4 bispecific AK104 and bevacizumab helps people with recurrent or persistent ovarian clear cell carcinoma.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guanzhou, Guangdong · NCT06540729

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

• Bevacizumab for severe HHT-related nosebleeds

  This study tests whether bevacizumab can help people with hereditary hemorrhagic telangiectasia who have severe nosebleeds.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07828015

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.